Dhia J Al-Timimi1, Mohammad T Rasool2, Dhia M Sulaiman3. 1. Professor, Department of Clinical Biochemistry, College of Medicine, University of Duhok , Duhok, Kurdistan Region, Iraq . 2. Assistant Professor, Department of General Medicine, Duhok Center for Rheumatic Disease and Medical Rehabilitation , Duhok, Kurdistan Region, Iraq . 3. Lecturer, Department of Clinical Biochemistry, College of Medicine, University of Duhok , Duhok, Kurdistan Region, Iraq .
Abstract
BACKGROUND: Specific alleles present at the HLA-DR/DQ loci seem to be associated with disease activity of rheumatoid arthritis. AIM: In the present study, our aim was to investigate the distribution of HLA-DR/DQ alleles among Kurd patients with rheumatoid arthritis and to ascertain their relationship with disease activity. MATERIALS AND METHODS: Sixty five patients with rheumatoid arthritis (RA) and 65 apparently healthy subjects participated in the study. Diagnosis and disease activity were confirmed. Blood analyses, including those of laboratory markers of disease activity, were done. The 28 joint disease activity score (DAS-28) was calculated. HLA-DR/DQ typing was performed by polymerase chain reaction (PCR).The association between HLA-DR/DQ genotypes and disease activity was determined. RESULTS: The most frequent alleles which were identified in RA patients were HLA-DRBI*01(23.1%) and HLA-DQBI*6(34.6%), whereas in healthy subjects, they were HLA-DRBI*11(17.7%) and HLA-DQBI*03(35.4%). Patients with active disease had high frequencies of HLA-DQBI*6 (40.0%) as compared to those with moderate disease activity (16.7%); OR=3.33. Patients with severe RA had increased frequencies of HLA-DQBI*6 (56.3%) as compared to those with mild RA (10.0%); OR = 11.57. Patients with positive rheumatoid factor (RF) and positive Anti-citrullinated peptide antibody (Anti-CCP), also had high frequencies of HLA-DQBI*06 (38.4% and 39.4%) as compared to frequencies of 11.1% and 15.4% which were seen in patients with negative rheumatoid factor and negative anti-CCP (OR= 4.98 and3.10) respectively. CONCLUSION: HLA-DQBI*06 was found to be more common in Kurd patients and it was significantly associated with disease activity; this may indicate a high risk for developing a more progressive type of the disease.
BACKGROUND: Specific alleles present at the HLA-DR/DQ loci seem to be associated with disease activity of rheumatoid arthritis. AIM: In the present study, our aim was to investigate the distribution of HLA-DR/DQ alleles among Kurd patients with rheumatoid arthritis and to ascertain their relationship with disease activity. MATERIALS AND METHODS: Sixty five patients with rheumatoid arthritis (RA) and 65 apparently healthy subjects participated in the study. Diagnosis and disease activity were confirmed. Blood analyses, including those of laboratory markers of disease activity, were done. The 28 joint disease activity score (DAS-28) was calculated. HLA-DR/DQ typing was performed by polymerase chain reaction (PCR).The association between HLA-DR/DQ genotypes and disease activity was determined. RESULTS: The most frequent alleles which were identified in RApatients were HLA-DRBI*01(23.1%) and HLA-DQBI*6(34.6%), whereas in healthy subjects, they were HLA-DRBI*11(17.7%) and HLA-DQBI*03(35.4%). Patients with active disease had high frequencies of HLA-DQBI*6 (40.0%) as compared to those with moderate disease activity (16.7%); OR=3.33. Patients with severe RA had increased frequencies of HLA-DQBI*6 (56.3%) as compared to those with mild RA (10.0%); OR = 11.57. Patients with positive rheumatoid factor (RF) and positive Anti-citrullinated peptide antibody (Anti-CCP), also had high frequencies of HLA-DQBI*06 (38.4% and 39.4%) as compared to frequencies of 11.1% and 15.4% which were seen in patients with negative rheumatoid factor and negative anti-CCP (OR= 4.98 and3.10) respectively. CONCLUSION: HLA-DQBI*06 was found to be more common in Kurd patients and it was significantly associated with disease activity; this may indicate a high risk for developing a more progressive type of the disease.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker Journal: Ann Rheum Dis Date: 2010-09 Impact factor: 19.103
Authors: Inmaculada Del Rincón; Daniel F Battafarano; Ramón A Arroyo; Frederick T Murphy; Michael Fischbach; Agustín Escalante Journal: Arthritis Rheum Date: 2003-04-15
Authors: Azra Arif I Ali; Tariq Moatter; Jawed Altaf Baig; Ahmed Iqbal; Azmat Hussain; Mohammad Perwaiz Iqbal Journal: J Pak Med Assoc Date: 2006-10 Impact factor: 0.781
Authors: Floris A van Gaalen; Jill van Aken; Tom W J Huizinga; Geziena M Th Schreuder; Ferdinand C Breedveld; Eric Zanelli; Walther J van Venrooij; Cornelis L Verweij; René E M Toes; René R P de Vries Journal: Arthritis Rheum Date: 2004-07
Authors: Carl Turesson; Daniel J Schaid; Cornelia M Weyand; Lennart T H Jacobsson; Jörg J Goronzy; Ingemar F Petersson; Gunnar Sturfelt; Britt-Marie Nyhäll-Wåhlin; Lennart Truedsson; Sonja A Dechant; Eric L Matteson Journal: Arthritis Res Ther Date: 2005-10-11 Impact factor: 5.156